Business
Proposed US pricing for Tutivia™
Proposed US pricing for Tutivia™.
About this update from Verici Dx Plc
[{"type":"text","content":"\n\n\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\")\n \nProposed US pricing for Tutivia™\nMedicare proposed gapfill median rate of $2,650 per test\n \nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that a gapfill median rate of $2,650 has been proposed for Tutivia™ for kidney transplant rejection by the Centers for Medicare & Medicaid Services (\"CMS\").\n \nMedicare is a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish payment rates for clinical laboratory tests under the Clinical Laboratory Fee Schedule (\"CLFS\") when no comparable test already exists on the CLFS.\n \nThe proposed rate was supported by the majority of Medicare Administrative Contractor (\"MAC\") localities, including Palmetto GBA, the MAC that will process future Medicare claims submitted for tests performed in Verici's Tennessee laboratory. This proposed rate is currently open for public comment before it is finalised later this year. Following finalisation, the price in the CLFS is valid for a period of three years from 1 January 2024, after which it is subject to further review.\n \nSara Barrington, Chief Executive Officer of Verici Dx, commented: \"This is another important milestone in our commercial strategy, and we are pleased the majority of MAC localities have proposed pricing for our Tutivia™ tests consistent with the resources required to develop and perform these tests. I look forward to the pricing being finalised later this year and securing reimbursement coverage in due course.\"\n \nEnquiries:\n \n\n\n\n\nVerici Dx\n\n\nwww.vericidx.com\n\n\n\n\nSara Barrington, CEO\n\n\nVia Walbrook PR\n\n\n\n\nJulian Baines, Chairman\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\n\n\nTel: +44 20 7496 3000\n\n\n\n\nAubrey Powell / Sam Butcher\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: +44 20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Stephanie Cuthbert /\nSam Allen\n\n\nMob: +44 7980 541 893 / +44 7796 794 663 /\n07502 558 258\n\n\n\n\n \nAbout Verici Dx plc www.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform ...